The impact of estrogen exposure on vascular risk in women with migraine

Keiko Ihara, MD, Keio University School of Medicine, Tokyo, Japan, talks through her study on the impact of estrogen exposure on vascular risk in women with migraine. Migraine is a contraindication to estrogen containing combined hormonal contraceptives because of the possible increased risk of vascular events. The nationwide electronic health record database study included almost 14,000 women diagnosed with migraine who used contraceptives. Overall, contraceptive use was not shown to significantly increase the risk of vascular events for women with migraine. In the subgroup of patients with migraine with aura, the risk of vascular events was not increased in those receiving contraceptives compared to those who were not. However, within the patients who used contraceptives, patients with migraine with aura had a significantly higher risk of vascular events than those with migraine without aura. This interview took place at the American Headache Society (AHS) Annual Meeting 2024 in San Diego, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.